Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2022
Verzenio (abemaciclib) receives positive reimbursement recommendation from CADTH for early breast cancer
1 November 2022 - Lilly Canada announced today that CADTH has issued their final reimbursement recommendation for Verzenio (abemaciclib) in ...
Posted by Michael Wonder on 01 Nov 2022
PHARMAC seeks feedback on the funding of paediatric cancer medicines
2 November 2022 - PHARMAC is seeking feedback on rule 8.1b of the Pharmaceutical Schedule – a unique exception that ...
Posted by Michael Wonder on 01 Nov 2022
First immunotherapy for patients with a potentially life threatening type of non-melanoma skin cancer now available on the PBS
1 November 2022 - Australians with a potentially life-threatening type of non-melanoma skin cancer will for the first time, have ...
Posted by Michael Wonder on 01 Nov 2022
Schedule of Pharmaceutical Benefits - 1 November 2022
1 November 2022 - The November 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Nov 2022
1 November 2022 updates as part of the digital transformation of Authority Required (Written) PBS listings
1 November 2022 - From 1 November 2022, the PBS listings for certain medicines will be updated as part of the ...
Posted by Michael Wonder on 31 Oct 2022
Expanded access to COVID-19 oral antiviral treatments on the PBS
1 November 2022 - Expanded eligibility criteria for COVID-19 oral anti-viral treatments (Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and ritonavir) ...
Posted by Michael Wonder on 31 Oct 2022
New Zealand Pharmaceutical Schedule - 1 November 2022
1 November 2022 - The November 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2022
Department of Health tweaks the agenda for this week's PBAC meeting
28 October 2022 - The is one late change to the agenda for the November meeting. ...
Posted by Michael Wonder on 28 Oct 2022
Public Summary Documents – July 2022 PBAC meeting
28 October 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2022 PBAC ...
Posted by Michael Wonder on 27 Oct 2022
Health technology assessment review – frequently asked questions
27 October 2022 - The Department of Health & Aged Care has produced a two page summary on the upcoming ...
Posted by Michael Wonder on 27 Oct 2022
Evidence based drug delivery for rare diseases: the role of digitisation
25 October 2022 - Digitisation has potential when it comes to making clinical development for the care of rare diseases more ...
Posted by Michael Wonder on 27 Oct 2022
PMPRB finds ultra-rare drug Procysbi is excessively priced
26 October 2022 - On 1 September 2022, a Panel of the Patented Medicine Prices Review Board issued a decision that ...
Posted by Michael Wonder on 27 Oct 2022
Cheaper medicines legislation passed
27 October 2022 - The Australian Government’s legislation, which will see millions of Australians pay 29% less for scripts with the ...
Posted by Michael Wonder on 27 Oct 2022
Independent chair of health technology assessment review will drive major reform of Australia’s health system
27 October 2022 - Medicines Australia welcomes the appointment of Adjunct Professor Debora Picone AO as independent Chair of the ...
Posted by Michael Wonder on 27 Oct 2022
Reference Committee for the health technology assessment policy and methods review
27 October 2022 - On 6 September 2021, the Commonwealth entered into a new Strategic Agreement in relation to reimbursement, ...